Purpose: As well as functioning as a ligand that is selectively internalized by cells overexpressing human epidermal growth factor receptor-2 (HER2), HApt can exert cytotoxic effects by inducing cross-linking and subsequent translocation of HER2 to cytoplasmic vesicles, such downregulation of HER2 inhibits cell proliferation and induces apoptosis. We aimed to exploit the potential of HApt as both a targeting agent and antagonist to maximize the efficacy of mesoporous silica nanoparticle (MSN)-based drug release systems for HER2-positive breast cancer. Materials and methods: We fabricated novel HApt aptamer-functionalized pH-sensitive β-cyclodextrin (β-CD)-capped doxorubicin (DOX)-loaded mesoporous silica nanoparticles (termed MSN-BM/CD-HApt@DOX) for targeted delivery and selective targeting of HER2-positive cells. MSN-functionalized benzimidazole (MSN-BM) was used to load and achieve pH stimuli-responsive release of the chemotherapeutic agent doxorubicin (DOX). β-cyclodextrin was introduced as a gatekeeper for encapsulated DOX and HApt as a selective HER2-targeting moiety and biotherapeutic agent. Results: Physical and chemical characterizations (FT-IR, XRD, TEM and BET) confirmed successful construction of MSN-BM/CD-HApt@DOX nanoparticles. In vitro release assays verified pH-sensitive DOX release. MSN-BM/CD-HApt@DOX (relative DOX concentration, 3.6 μg/mL) underwent HER2-mediated endocytosis and was more cytotoxic to HER2-positive SKBR3 cells than HER2-negative MCF7 cells. MSN-BM/CD-HApt@DOX also exhibited better uptake and stronger growth inhibition in SKBR3 cells than the control MSN-BM/CD-NCApt@DOX functionalized with a scrambled nucleotide sequence on CD. Overall, intracellular delivery of DOX and the biotherapeutic agent HApt resulted in synergistic cytotoxic effects in HER2-positive cancer cells in comparison to either DOX or HApt alone. Conclusion: MSN-BM/CD-HApt@DOX enables HER2-mediated targeting and biotherapeutic effects as well as pH-responsive DOX drug release, resulting in synergistic cytotoxic effects in HER2-overexpressing cells in vitro. This novel nanocarrier could potentially enable specific targeting to improve the efficacy of chemotherapy for HER2-positive cancer.
1 September 2020 in Colloids and Surfaces B: Biointerfaces
The principal problem in the area of drug delivery is achieving better selectivity and controllability. A new core–shell nanoparticle composite (denoted MSN@Tf@Polymer) with dual-pH-sensitivity has been prepared as a drug carrier for intracellular drug delivery and release. MSN@Tf@Polymer consists of mesoporous silica nanoparticles (MSN), green-transferrin (Tf) and diblock copolymer (poly-2-diisopropylamino ethylmethacrylate-b-methoxy-poly ethyleneglycol: mPEG45-PDPAn). The core–shell structure is self-assembled layer by layer. Results show that nearly 80% doxorubicin hydrochloride (DOX) loaded in MSN@Tf@Polymer could be released in 5 h at pH 5.0, which is an improvement from the results obtained at pH 6.5 and pH 7.4. MTT assay and fluorescence inversion microscope experiments indicate that MSN@Tf is successfully taken up by liver cancer cells (Huh7) without apparent cytotoxicity, and Tf has strong intensity of fluorescence for subcellular localization. Confocal laser scanning microscopy (CLSM) experiments indicate that MSN@Tf@Polymer is able to enter the lysosome of the tumor cells. Furthermore, cell apoptosis experiments prove that DOX loaded in MSN@Tf@Polymer has the best anti-tumor effect compared with free DOX and DOX in bare MSN. MSN@Tf@Polymer has high biocompatibility, enhanced drug loading, site-specific delivery and in situ stimulus release and will also hopefully be applied as an intracellular drug delivery system.
Entry inhibitors are promising novel antivirals against hepatitis B virus (HBV) infection. The existing potential entry inhibitors have targeted the cellular receptor(s). In this study, we aim to develop the first entry inhibitor that inhibits HBV infection via targeting viral particles. The preS1 segment of the large envelope glycoprotein of HBV is essential for virion attachment and infection. Previously, we obtained a preS1-binding short peptide B10 by screening a phage display peptide library using the N-terminal half of preS1 (residues 1 to 60, genotype C). We report here that by means of concatenation of B10, we identified a quadruple concatemer 4B10 that displayed a markedly increased preS1-binding activity. The main binding site of 4B10 in preS1 was mapped to the receptor binding enhancing region. 4B10 blocked HBV attachment to hepatic cells and inhibited HBV infection of primary human and tupaia hepatocytes at low nanomolar concentrations. The 4B10-mediated inhibition of HBV infection is specific as it did not inhibit the infection of vesicular stomatitis virus glycoprotein pseudotyped lentivirus or human immunodeficiency virus type 1. Moreover, 4B10 showed no binding activity to hepatic cells. In conclusion, we have identified 4B10 as a promising candidate for a novel class of HBV entry inhibitors.
One growing issue is how to use the weakly acidic conditions in endosomes/lysosomes for designing highly pH-sensitive drug carriers to deliver chemotherapeutic drugs accurately. In this paper, pH-sensitive amphiphilic triblock copolymers PEG8-PDPAn-PEG8 (n = 30, 50 and 100) were synthesized. Micelles composed of the copolymers were found to enter into lysosomes using a lysosome tracker method. The pH-sensitivity makes the micelles stable at pH 7.4 but swell and become looser at pH 6.0 due to protonation. Then, doxorubicin (DOX) was efficiently encapsulated in the hydrophobic cores of the micelles and released continuously in a weakly acidic environment. Cell toxicity assays were carried out using 2 human cell lines (HEK293 and Huh7) and showed good cyto-compatibility. In vitro cell viability tests proved that the DOX-loaded micelles could be more efficiently taken up by Huh7 tumor cells than free DOX, as well as actively trigger intracellular DOX release. Furthermore, in addition to small molecules (DOX), the copolymer micelles could also deliver macromolecules (such as transferrin, which could not enter into cells by itself) into lysosomes/endosomes. These nontoxic and multifunctional micelles can serve as a promising treatment candidate for efficient intracellular drug delivery and real-time monitoring.
Human noroviruses (HuNoVs) are the main pathogens that cause acute gastroenteritis and lead to huge economic losses annually. Due to the lack of suitable culture systems, the pathogenesis of HuNoVs and the development of vaccines and drugs have progressed slowly. Although researchers have employed various methods to culture HuNoVs in vitro in the last century, problems relating to the irreducibility, low viral titer, and non-infectiousness of the progeny virus should not be ignored. In 2016, researchers achieved the cultivation and successive passaging of some HuNoV genotypes using human intestinal enteroids, initially demonstrating the potential use of organoids in overcoming this challenge. This paper reviews the efforts made in the last 20 years to culture HuNoVs in vitro and discusses the superiority and limitations of employing human intestinal enteroids/organoids as an in vitro culture model for HuNoVs.